(Q35917262)

11 August 2017

1 reference

title

Advances in the management of Chlamydia pneumoniae infections (English)

1 reference

11 August 2017

Chlamydia pneumoniae

1 reference

based on heuristic

inferred from title

author name string

Margaret R Hammerschlag

series ordinal

1

1 reference

11 August 2017

language of work or name

1 reference

1 October 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

493-503

1 reference

Chlamydia pneumoniae sp. nov. for Chlamydia sp. Strain TWAR

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Comparative genomes of Chlamydia pneumoniae and C. trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Genome sequencing and our understanding of chlamydiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Comparative in vitro activity of garenoxacin against Chlamydia spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Growth and development of tetracycline-resistant Chlamydia suis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Macrolide resistance conferred by base substitutions in 23S rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Is asthma an infectious disease?: Thomas A. Neff lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Persistent infection with Chlamydia pneumoniae following acute respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Antibiotics and risk of subsequent first-time acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Antibiotic use and risk of ischemic stroke in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.493

21 January 2018

Identifiers

DOI

10.1586/14787210.1.3.493

1 reference

11 August 2017

1 reference